Claims
- Protective barrier effect against airborne environmental irritants.
- Reduction of nasal symptoms such as nasal congestion, sneezing, nasal itching and rhinorrhea within 6 days.
- Reduced nasal congestion from day 1 of treatment.
- Reduced eye symptoms such as redness, itching and tearing within 6 days.
- Improvement in quality of life from the reduction of both nasal and ocular symptoms.
- Reduced need for allergic rhinitis medication.
- Prevent secondary infection and progression to a severe, chronic form.
- Improved patient well-being and sleep quality.
Mode of action
ALLERPUR stands out with its formula that not only provides quick relief but also offers a long-term solution to allergic rhinitis caused by airborne environmental irritants.
- Protective Barrier: It forms a thin, protective film over the mucosa, creating a mechanical barrier that shields it from direct contact with airborne environmental irritants.
- Mechanical Cleaning: Utilizes osmotic action to attracts, traps, and removes contaminants, helping to reduce inflammation and alleviate symptoms.
- Cellular Repair: Promotes the healing and regeneration of the nasal mucosa, restoring its natural barrier against future allergic triggers.
Clinical Trial
A randomized, double-blind clinical trial highlighted its effectiveness in reducing nasal congestion and itching sensation, leading to a noticeable improvement in quality of life. The trial also showed significant reductions in total nasal and ocular symptoms within weeks.
TYPE OF TRIAL: Randomized, double-blind clinical trial against placebo | 3 weeks
PATIENTS: N=49 | Test product = 32 ; Comparator = 17
Main results:
TOTAL NASAL SYMPTOMS
- 21 % reduction in total nasal symptoms within 6 days
- 36 % reduction in total nasal symptoms within 12 days
- 73 % reduction in total nasal symptoms within 22 days
TOTAL OCULAR SYMPTOMS
- 18 % reduction in total ocular symptoms within 6 days
- 32 % reduction in total ocular symptoms within 12 days
- 60 % reduction in total ocular symptoms within 22 days
OTHER PARAMETERS
- 46 % improvement in RQLQ score (Rhinoconjunctivitis Quality of Life Questionnaire)
- Rescue medicine score : 23.52% for placebo group vs 3.44 % for test group
Product Details
- Indication: Treatment of mild-to-moderate, intermittent, allergic rhinitis caused by environmental irritants.
- Composition: Filmogenic glycerol, HPC, Allercyanidin: association of Vaccinium myrtillus, Hedera helix, Curcuma longa, and EO: Mentha piperita. Potassium Sorbate, Sodium Benzoate, Citric Acid.
- Presentation: Nasal spray 15ml.
- Class: MDR Class IIa.
- Direction: 3 sprays in each nostril, 3 times a day. Treatment duration : 3 weeks.
- Precautions: For topical use only (nasal cavity). Keep out of reach and sight of children.
- Age: Suitable for adults 18 and over.
- Exclusions : ALLERPUR should not be used in certain situations due to limited safety data. It is contraindicated if you have an uncontrolled chronic disease, a condition that may impair breathing (such as bronchopneumonia), or a nasal infection requiring specific treatment. Avoid use if you have a level III septal deviation, nasal polyps, or other causes of significant nasal congestion. ALLERPUR is also not recommended for those who have undergone nasal surgery within the past year or for individuals with a current diagnosis of glaucoma, cataracts, or ocular herpes simplex. Additionally, if you suffer from severe chronic allergic rhinitis, or are taking long-term antihistamines, immunosuppressants, ALLERPUR should not be used. Furthermore, ALLERPUR is not suitable for use by pregnant or breastfeeding women.
- Storage conditions: Below 25°C.
- Legal manufacturer: VITROBIO (France).
- Product code: PC.